{"id":11126,"date":"2023-02-09T00:03:22","date_gmt":"2023-02-08T16:03:22","guid":{"rendered":"https:\/\/newsletter.sinica.edu.tw/en\/?p=11126"},"modified":"2024-03-13T09:19:03","modified_gmt":"2024-03-13T01:19:03","slug":"structural-basis-for-a-conserved-neutralization-epitope-on-the-receptor-binding-domain-of-sars-cov-2","status":"publish","type":"post","link":"https:\/\/newsletter.sinica.edu.tw/en\/11126\/","title":{"rendered":"Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2"},"content":{"rendered":"
The COVID-19 pandemic seems to be fading away from our daily life, but the threat of a recurring circulation of new variants still haunts. While the vaccines continue being developed for a preventive purpose, the neutralizing antibodies stand in the last line of defense as a therapeutic tool. In the latest publication on “Nature Communications”, exciting findings were reported by a collaborative team led by Dr. Che Ma in the Genomics Research Center and Dr. Kuan-Ying Huang in the National Taiwan University Hospital. From the locally recruited individuals in Taiwan, they identified a panel of eight monoclonal antibodies that are all targeting a cryptic yet conserved epitope of the receptor binding domain (RBD) of the surface Spike protein of SARS-CoV-2.<\/p>\n